Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors
Status:
Withdrawn
Trial end date:
2021-08-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies ferumoxytol in the magnetic resonance imaging of pediatric
patients with brain tumors. Magnetic resonance imaging using ferumoxytol may help in viewing
a brain tumor and blood vessels in and around the tumor in a different way than the standard
gadolinium-based contrast agent. Imaging with this experimental contrast agent may give
doctors more information about tumor blood supply and the extent of the tumor itself.
Phase:
Phase 2
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
AMAG Pharmaceuticals, Inc. National Cancer Institute (NCI) Oregon Health and Science University